Physician profile
Donovan D Clark
NPI 1235199100
$14,457.02
in general payments reported to CMS, 2019-2025
18 companies · $2,747 in 2025
The $2,747 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $446 · 2021: $1,439 · 2022: $1,897 · 2023: $3,188 · 2024: $3,605 · 2025: $2,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,513 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,512.73 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,094.24 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,032.68 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $1,882.43 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,759.22 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $1,269.84 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $1,267.77 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $946.48 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $928.17 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $779.12 | 2019-2025 | Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $430.66 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $278.29 | 2019-2022 | |
| Allergan, INC. | $217.19 | 2019 | |
| Axsome Therapeutics, INC. | $204.60 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $203.59 | 2023-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $115.47 | 2019-2024 | Trintellix |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $21.47 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.75 | 2023 | Abilify Asimtufii |
| Corium, LLC | $9.05 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donovan Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.